Adagrasib elicits good responses in KRASG12c-mutant lung cancer, active in other solid tumors.
Strategy for testing therapies in pediatric cancers saves resources while achieving results similar to conventional approach.
CD19 expression in non-B cells may contribute to neurotoxicity associated with CAR T-cell therapies.
Study suggests targeting exhausted T cells to improve treatment in patients with large B-cell lymphoma.
Three researchers pinpoint a leading cause of hepatocellular carcinoma, sparking screening, treatment efforts.
Adjuvant use of CDK4/6 inhibitor plus endocrine therapy cuts recurrence risk for HR-positive, HER2-negative disease.
Emmanuelle Charpentier and Jennifer Doudna lauded for gene-editing tool now entering oncology trials.
Well tolerated, sotorasib elicited responses in about a third of patients with KRASG12C mutations.
Automated point-of-care system offers cheaper, more efficient option for diagnosing disease.
Allelic state and microbes influence mutant p53–induced tumorigenesis.
For breast cancer, intermittent fasting or a fasting-mimicking diet enhances treatment efficacy, reduces side effects.
Tumor vesicles carry characteristic proteins that may support disease diagnosis.
Differences in genetic risk and tumor biology may contribute to disparities in prostate cancer and multiple myeloma.
Says virus likely to cause a “substantial number” of deaths in patients with cancer who aren't infected; discusses personalizing lung cancer treatment.
Androgen blockade, BTK inhibition being evaluated to tackle viral entry, hyperinflammation in severe disease.
The PD-1 antibody camrelizumab plus the VEGFR2 inhibitor apatinib had efficacy in a phase II trial.
OnlineFirst articles are published online before they appear in a regular issue of the journal. Cancer Discovery publishes two types of OnlineFirst articles.
OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.
Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.
Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.
When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).
While an article is OnlineFirst, it may be cited as shown in the following example:
Elizabeth A. Platz et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment (April 1, 2011) Cancer Discov, 10.1158/2159-8274.CD-10-0020.
Sign up to be notified each time OnlineFirst articles are posted in Cancer Discovery.